Efficacy of Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir with Ribavirin in Liver Transplant Recipients with Recurrent HCV GT1
The CORAL-I trial evaluated the safety and efficacy of the 3D regimen (ombitasvir-paritaprevir-ritonavir + dasabuvir) combined with ribavirin for 24 weeks in liver transplant recipients with recurrent HCV genotype 1. The study included treatment-naive individuals after transplantation, with specific
0 views • 8 slides
Effectiveness of Daclatasvir and Sofosbuvir in HCV Genotype 3: Insights from ALLY-3 Study
Study on the efficacy of Daclatasvir and Sofosbuvir in treating Hepatitis C Virus (HCV) Genotype 3, involving treatment-naive and treatment-experienced patients. The Phase 3 trial showcased promising results in achieving SVR12, with detailed patient characteristics, drug dosing, and baseline charact
0 views • 10 slides
Therapeutic Trials in HIV/HCV Coinfection: ION-4, Ally-2, and Viroteam 2015
In the study of therapeutic trials in HIV/HCV coinfection between 2014-2015, notable trials included ION-4 with LDV/SOF treatment for 12 weeks in HCV/HIV co-infection patients, showing high SVR rates in both treatment-naive and experienced patients. Another trial, Ally-2, involved Daclatasvir and So
0 views • 15 slides
Comparison of SOF+RBV vs PEG-IFN-2a+RBV for HCV Genotype 2 and 3 Treatment
FISSION Study compared the efficacy of SOF+RBV and PEG-IFN-2a+RBV for HCV genotypes 2 and 3 in treatment-naive patients with chronic HCV infection. The study included 256 participants in the SOF+RBV group and 243 in the PEG-IFN-2a+RBV group. The primary objective was to determine the non-inferiority
0 views • 6 slides
Study on GZR, EBR, and MK-3682 for Chronic HCV Infection
The C-CREST study, Part A, focuses on the Phase II design of GZR, EBR, and MK-3682 treatment for genotypes 1, 2, and 3 in chronic HCV infection. The study includes baseline characteristics, SVR12 endpoint, impact of NS5A RAVs, and treatment outcomes. Results show promising SVR rates with different r
0 views • 8 slides